openwiki-wiki/commitments.md

Commitments

Concrete work tasks, follow-ups, approvals, and scheduled items extracted from Gmail, Notion, Slack, direct mentions, and other work-relevant sources. Personal errands and life admin live in /personal-logistics.md instead.

Active

china-cde-cell-gene-therapy-rules-2026: verify CDE classification scope for Chinese pharma / CDMO conversations

• Owner: me
• Source: web-search — cisema.com 2026-07-24 (China CDE Defines Classification Rules for Cell & Gene Therapy Drugs)
• Due: unscheduled
• Status: open
• Notes: Single credible regulatory-trade source. Pull the NMPA/CDE-direct release before the next vendor sync; check whether any active CellShot-TriArm or ClinoReactor-class deals depend on the new classification scope.

celvivo-clinoreactor-thewell-bioscience-xeno-free: verify TheWell Bioscience co-marketing signal on next CelVivo check

• Owner: me
• Source: web-search — thewellbio.com 2026-07-21 / 2026-07-23 / 2026-07-25 (Xeno-Free Cell Culture Media, Stem Cell Culture Product Guide, Apical-Out Organoids white paper — all explicitly name "CelVivo ClinoReactor™")
• Due: unscheduled
• Status: open
• Notes: First vendor-anchored CelVivo ClinoReactor signal in any Tavily pull (prior pulls returned only MO:BOT / generic organoid). TheWell Bioscience is a hydrogel-media partner; their workflow pages position ClinoReactor as the scale-up vessel for apical-out organoids + hMSC expansion. Confirm with CelVivo whether this is a sanctioned co-marketing arrangement and whether it maps to any active Chinese pharma / CDMO deal.

china-order-no-818-clinical-translation: verify Order No. 818 (effective 2026-05-01) scope for Chinese pharma / CDMO conversations

• Owner: me
• Source: web-search — BetaLife LinkedIn 2026-07 (top score 0.779; explicitly cites "Order No. 818, effective May 1, 2026" with accelerated clinical-translation pathway); Tavily answer text corroborates; Roots Analysis re-mentions broader China cell-therapy regulatory pattern
• Due: unscheduled
• Status: open
• Notes: Single primary source (BetaLife SG LinkedIn) but the regulation itself is a published policy text — Order No. 818 creates an accelerated clinical-translation pathway at qualified hospitals for cell therapy and 3D bioprinting after demonstrating safety and preliminary efficacy. This is the clinical-translation counterpart to the existing china-cde-cell-gene-therapy-rules-2026 item (which is about classification / CMC planning). Both items matter: classification scope drives dossier content vendors need to assemble; the clinical-translation pathway drives which hospitals can host first-in-human studies. Pull the NMPA / State Council Order No. 818 direct text before the next vendor sync; check whether any active CellShot-TriArm or ClinoReactor-class deal depends on whether the buyer hospital qualifies as a "qualified hospital" under the regulation.

cellink-bio-x-gen3-customer-evidence: verify Cellink BIO X Gen 3 / BIO X6 customer pipeline on next Cellink check

• Owner: me
• Source: web-search — Nuclear Mechano-Oncology LinkedIn 2026-07 (score 0.601; "our new BIO X Gen 3 bioprinter has now been installed … first hands-on training session"); CELLINK official LinkedIn 2026-07-28 (score 0.287; BIO X6 at University of Miami 3D Bioprinting Facility); third-party market report LinkedIn 2026-07-28 (score 0.659; Cellink revenue uptick following strategic acquisitions); appellaser.ro practical selection guide 2026-07-24 (score 0.303; BIO X Gen 3 general-purpose positioning)
• Due: unscheduled
• Status: open
• Notes: First vendor-anchored Cellink signal in any Tavily pull after 5 prior pulls of zero Cellink product mentions. Four distinct sources: customer install LinkedIn (Eastern Europe), vendor LinkedIn (CELLINK U. Miami), market report, independent selection guide. Verify with Cellink whether the BIO X Gen 3 / BIO X6 nomenclature is current product naming or if one is being deprecated; whether any of the named customer accounts (Nuclear Mechano-Oncology; U. Miami 3D Bioprinting Facility) maps to active Chinese pharma R&D / CDMO opportunities. Companion to the existing celvivo-clinoreactor-thewell-bioscience-xeno-free item.

china-cgt-2026-july-developments: monitor gene-editing trial death fallout + Merck–Bio-Techne / CARsgen satri-cel context for Chinese pharma / CDMO positioning

• Owner: me
• Source: web-search — Straits Times 2026-07-24 (score 0.313; patient death in China gene-editing trial draws fire); LiveScience 2026-07-24 (score 0.145; 6-year-old girl, investigation into gene-therapy regulations); SCMP 2026-07-29 (score 0.203; "Fear of policy backlash" — same-day coverage with this Tavily pull); Roots Analysis 2026-07-24 (score 0.669; Merck–Bio-Techne $11.3B acquisition June 2026 + CARsgen satri-cel CAR-T approval for stomach cancer June 2026); BioSpace 2026-07-27 (score 0.535; Summit/Merck China-first regulatory navigation)
• Due: unscheduled
• Status: open
• Notes: Material new development in the China regulatory lane — sits on top of the existing china-cde-cell-gene-therapy-rules-2026 and china-order-no-818-clinical-translation items, not replacing them. Two positive signals (Merck–Bio-Techne acquisition; CARsgen satri-cel solid-tumor CAR-T approval) show the China CGT manufacturing environment is consolidating around advanced therapeutics. One negative signal (gene-editing trial death + published regulatory backlash) could foreshadow stricter CDE / NMPA / hospital-level oversight and tighter qualification criteria for "qualified hospitals" under Order No. 818. Together these affect: (a) qualification timelines for the CellShot-TriArm and ClinoReactor-class deals Robin has in flight, (b) which "qualified hospitals" remain eligible to host first-in-human studies, (c) whether CelVivo / 3Brain / Cellink vendor positioning for Chinese pharma R&D / CDMO accounts needs to change tone (e.g. emphasize safety documentation, IRB-grade workflows). Pull NMPA / hospital-IRB statements on the gene-editing trial case before next Chinese customer conversation.

3brain-coreplate-2026-conference-positioning: verify current CorePlate campaign and retrieve application material on next 3Brain check

• Owner: me
• Source: web-search — 3Brain official website plus 3Brain organization material captured through LinkedIn in Tavily pull 7 (2026-07-30); the dated result is 2026-07-25 and names ISSCR 2026 booth 412, while the company page also names ELRIG Drug Discovery booth 4
• Due: unscheduled
• Status: open
• Notes: First credible direct 3Brain evidence after five Tavily pulls dominated by an unrelated EEG-paper mis-attribution. Vendor material positions CorePlate-enabled HD-MEA for high-resolution, scalable functional readouts from iPSC neuronal/cardiac models, brain organoids, assembloids, and 3D spheroids. Confirm which conference posts are current, obtain the named posters/application notes, and map them to Chinese neural-organoid and pharma-screening prospects. This pull does not establish CorePlate 1W/6W load force or Sample Holder Set details.

celvivo-clinostar-2-nams-demo-2026: verify product naming and campaign provenance on next CelVivo check

• Owner: me
• Source: web-search — Instagram snippets surfaced in Tavily pull 7 (2026-07-30): ClinoStar webinar copy (DbaUZjIjMgK), NexUs Locus on-site demo copy dated 2026-07-24 (DbKYC4NBtrN), and ClinoStar 2 NAMs positioning (DbSl7nkoFjK)
• Due: unscheduled
• Status: open
• Notes: Watchlist lead, not a confirmed launch or customer win. Verify that the posts come from CelVivo or an authorized distributor, whether ClinoStar 2 is current official product naming, and whether the NexUs Locus live demo produced reusable data or contacts. The result set does not support Tavily's “installed base” language; one malformed duplicate URL was discarded.

itx-24h-host-build-2026-q3: finish assembly + Ubuntu + Hermes install on Robin's 24h host (paused since hardware is 10/11 arrived)

• Owner: me
• Source: git-repo — 03-Resources/ITX-24h-Host/ITX_24h_Host_v18_Config_2026-07-31.md (Obsidian vault, untracked as of fetch 2026-07-31T18:08:12Z)
• Due: unscheduled (waiting for the last #8 / #9 cable parts on hand; once on hand, finish the assembly + software stack)
• Status: open
• Notes: Personal-infra work item (workflow-tooling priority LOW), not vendor-anchored — logged here because it is source-anchored to Robin's actual vault work per the brief's commitments.md rule ("only real Robin commitments"). Plan: mATX + i5-12400 + DDR4-2666 32G + 板载 Realtek 1Gb + Intel PRO/1000 GT (¥2,985.82, 10/11 parts on hand). Two 网卡 VLAN: 192.168.31.100 → 主力机 Win 11 SSH, 10.10.10.254 → 主力 NAS RAGFlow. Post-assembly steps: Ubuntu Server 22.04 LTS install, partition / (GM7 512G) + /data (mSATA 512G), Docker, dual-NIC 静态 IP, 主力机 SSH key 免密, NAS RAGFlow API 接入, 安装 Hermes Agent, 24h 跑功耗 soak test. The host has no vendor-product overlap; not promoted to /themes.md row because that index is reserved for recurring workflow signals.

Completed recently